313548-31-1

Basic information

• Product Name: methyl 3-(2-(4-adamantan-1-ylphenoxy)acetamido)benzoate
• Synonyms: methyl 3-(2-(4-adamantan-1-ylphenoxy)acetamido)benzoate
• CAS NO: 313548-31-1
• Molecular Weight: 419.521
• Mol File: 313548-31-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl 3-(2-(4-adamantan-1-ylphenoxy)acetamido)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(2-(4-adamantan-1-ylphenoxy)acetamido)benzoate(313548-31-1)
• EPA Substance Registry System: methyl 3-(2-(4-adamantan-1-ylphenoxy)acetamido)benzoate(313548-31-1)

Safety Data

• Hazardous Substances Data: 313548-31-1(Hazardous Substances Data)

Upstream product

• 29799-07-3 4-adamantylphenol 
• 52804-25-8 (4-adamantyl-1-yl-phenoxy) acetic acid ethyl ester 
• 4518-10-9 Methyl 3-aminobenzoate 
• 52804-26-9 (4-adamantan-1-yl-phenoxy)acetic acid 

Downstream Products

• 313548-34-4 3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-benzoic acid 

Relevant articles and documents

NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a compound exhibiting inhibitory activity of at least one of malate dehydrogenases I (MDH1) and malate dehydrogenases 2 (MDH2), and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The inventors of the present invention have experimentally confirmed that the compound exhibiting the MDH1 and/or MDH2 inhibitory activity has an inhibitory effect on mitochondrial respiration in cancer cells, an excellent inhibitory effect on cancer cell growth, etc. Thus, the compound of the present invention is expected to be effectively used as a pharmaceutical composition for treating cancer.

COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors

Structural modification of a compound discovered during screening using an HRE-dependent reporter assay has revealed a novel class of HIF-1 inhibitors, which potently inhibit the HIF-1α protein accumulation and its target gene expression under hypoxic conditions in human hepatocellular carcinoma Hep3B cells.